Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 114.79M P/E - EPS this Y -59.70% Ern Qtrly Grth -
Income -54.43M Forward P/E -0.94 EPS next Y -25.60% 50D Avg Chg -64.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -72.00%
Dividend N/A Price/Book 0.38 EPS next 5Y - 52W High Chg -82.00%
Recommedations 1.80 Quick Ratio 27.56 Shares Outstanding 37.62M 52W Low Chg 21.00%
Insider Own 4.96% ROA -13.09% Shares Float 30.43M Beta -
Inst Own 75.18% ROE -18.43% Shares Shorted/Prior 2.25M/2.75M Price 3.05
Gross Margin - Profit Margin - Avg. Volume 819,516 Target Price 32.60
Oper. Margin - Earnings Date May 11 Volume 2,457,716 Change 2.01%
Athira Pharma, Inc. News
06/22/22 Athira Pharma's stock plummets after disappointing drug trial results
06/22/22 Athira Pharma stock loses two-thirds of its value after study of Alzheimer's treatment misses primary endpoint
06/22/22 Why Athira Pharma Stock Imploded Today
06/22/22 Athira says its Alzheimer's treatment did not meet endpoint in mid-stage trial; stock falls 68%
06/22/22 Athira Pharma Shares Fall To 52-Week Low - Read Why
06/22/22 Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
06/07/22 Athira Pharma Announces Formation of Scientific Advisory Board Comprised of Renowned Leaders in Neurology Research
05/22/22 What Kind Of Investors Own Most Of Athira Pharma, Inc. (NASDAQ:ATHA)?
05/19/22 Shareholders Approve the Election of All Three Athira Director Nominees at 2022 Annual Meeting
05/17/22 Athira shareholder suspends push for board control days before shareholders' meeting
05/16/22 Athira Issues Statement in Response to Richard A. Kayne’s Suspension of His Proxy Contest
05/16/22 Athira Pharma Presents Preclinical Data at the 2022 Peripheral Nerve Society (PNS) Annual Meeting
05/12/22 Athira Pharma Reports First Quarter 2022 Financial Results and Provides Pipeline and Business Updates
05/11/22 Athira Urges Shareholders to Support its Director Nominees at May 19 Annual Meeting
05/09/22 Athira Pharma Extends Ongoing Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of Fosgonimeton (ATH-1017) for Mild to Moderate Alzheimer’s Disease
05/05/22 Leading Independent Proxy Advisory Firm Glass Lewis Recommends that Athira Shareholders Vote “FOR” All of Athira’s Highly Qualified Director Nominees
05/05/22 Athira Mails Letter to Shareholders Emphasizing the Company’s Strong Position and Qualified Board as it Enters Pivotal Chapter
05/04/22 Leading Independent Proxy Advisory Firm ISS Recommends that Athira Shareholders Vote on Athira’s WHITE Proxy Card
04/27/22 Athira leadership braces for challenge as shareholders' meeting approaches

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

ATHA Chatroom

User Image 117Cavanaugh Posted - 06/30/22

$ATHA My guess is that they will stagger announcements of insider buys over the next 3-4 weeks, hoping to get the share price up to $4.50 or so, and then in August announce the new analysis of the data to push this thing back into double digits where it belongs.

User Image MarketBeatInsiderTrades Posted - 06/30/22

Athira Pharma Insider Hans Moebius Buys $28,800.00 in $ATHA https://www.marketbeat.com/i/517122

User Image thesubmitter Posted - 06/30/22

$ATHA - hans makes 30k purchase, the man believe ig

User Image WizardsSleeve Posted - 06/30/22

$ATHA RAIN all over again boys. Congrats longs!

User Image toffernelson Posted - 06/30/22

$ATHA Up almost 20% in a week from the drop low point. Next few days will be interesting. If you look at BBIO: 1. Dropped $41 to $11 2. Bounced to $14 3. Lots of insider buying pushed it to $18 4. Then melted for 6 weeks to $7 Very similar patterns on these: HGEN, ALLK, AVIR, CRTX, SESN, ADGI.

User Image toffernelson Posted - 06/30/22

$ATHA In the upper ranges of my overall strategy. Watching closely tomorrow and might make an exit and take the loss. I have no doubt this bleeds to low $2.00s. It’s just a matter of timing and there’s better opportunities than waiting this out for another four to six weeks.

User Image cctranscripts Posted - 06/30/22

Athira Pharma, Inc.'s Chief Medical Officer just picked up 10,000 shares https://www.conferencecalltranscripts.com/summary/?id=11038241 $ATHA

User Image Quantisnow Posted - 06/30/22

$ATHA 📜 SEC Form 4: Moebius Hans bought $28,800 worth of shares (10,000 units at $2.88), increasing direct ownership by 23% to 52,955 units https://quantisnow.com/i/3097084?utm_source=stocktwits 45 seconds delayed.

User Image risenhoover Posted - 06/30/22

Insider Hans Moebius reports buying 10,000 shares of $ATHA for a total cost of $28,800.00 https://fintel.io/n/us/atha/moebius-hans?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=insider

User Image Newsfilter Posted - 06/30/22

$ATHA Form 4 (statement of changes in beneficial ownership of securities) filed with the SEC https://newsfilter.io/a/0fbbfd05e981dbcd6644252d328f251a

User Image viking1111 Posted - 06/30/22

$ATHA looking good atha.

User Image GoodKarmaCapital Posted - 06/30/22

$ATHA Institutions are not selling and the stick will continue recovering because the money is in fosgonimeton as a Monotherapy and they plan to present the full results at the upcoming Alzheimer’s Association International Conference July 31 to August 4. If you are a new investor here read the article so you can understand what is going on. "These data points are very encouraging as they indicate the expected pharmacological activity of fosgonimeton by parallel improvement on ERP P300 latency and ADAS-Cog11 and show a favorable safety profile over 6 months. This is the first-time monotherapy fosgonimeton has shown an effect on ADAS-Cog11, suggesting a potential cognitive benefit,” https://www.neurologylive.com/view/fosgonimeton-fails-reach-end-points-but-shows-mechanistic-potential-alzheimers

User Image GoodKarmaCapital Posted - 06/30/22

$ATHA Back to $10 we go. 💵💵💵💵

User Image zeph1985 Posted - 06/30/22

$ATHA i trust in this stock

User Image tradingSAC Posted - 06/30/22

added $ATHA at $3.06 🤞😊

User Image Dervy91 Posted - 06/30/22

$ATHA

User Image fabietto73 Posted - 06/30/22

$ATHA oh wow amazing

User Image Bigmoney4me Posted - 06/30/22

$SAVA $ATHA $ALZN yall got the wrong ones. $NRSN is the ticket

User Image ParabolicStonk Posted - 06/30/22

$NRSN 👈🏻 🏃🏻💨 BIG RUN! SQUEEEZE! TRAPPED SHORTS. Top gainer.Huge Alzheimer’s news, low float 4M, will sky rocket double digits! 300% CTB. No shares. LOAD UP CHEAP!! $SAVA 2.0 $ALZN $ATHA $LGVN

User Image The_Future Posted - 06/30/22

$ATHA huge short here. $3.10 very close then a super squeeze 🚀

User Image Bigmoney4me Posted - 06/30/22

$NRSN $SAVA $ALZN $ATHA folks NRSN is the right train !!

User Image TraderHabbit Posted - 06/30/22

$ATHA Here we go mr ……. 🥸 Don’t you worry keep selling your shit… we will take your money!! Pants down! Stock up ⬆️ This guy done shit … sounds like it he worried… Keep posting crap! We will take all your money! Thanks mate

User Image toffernelson Posted - 06/30/22

$ATHA More shares traded in the last hour than yesterday and it’s down 1%. Constant rejection at $3.00. Has not beat the weekly high $3.10. What happens when these daily swing traders get bored and leave?

User Image VortexPlayer Posted - 06/30/22

$ATHA @toffernelson How is that short position going genius? It seems @PLATINUM_TRADES @TraderHabbit @TimingTimingTiming @GoodKarmaCapital @Bigmoney4me @117Cavanaugh and all longs here are eating your lunch 😯 Did you cover already? Are you sleeping well at night? You ok?

User Image toffernelson Posted - 06/30/22

$ATHA A 1M+ candle sandwiched between to <10K candles… Seems legit…

User Image GoodKarmaCapital Posted - 06/30/22

$ATHA Solid momentum on solid data. Just a matter of time. Sending kind thoughts to the lone sad 🐻 in the forum although he probably covered already 😎

User Image Bigmoney4me Posted - 06/30/22

$NRSN between $ALZN $SAVA $ATHA and NRSN, NRSN might be the only game in town, I think so buy buy buy, do your dd in this space and you’ll probably agree with this short term price target here of.18+

User Image PLATINUM_TRADES Posted - 06/30/22

$ATHA I told you!! Don't listen to the sideline traders.. I got your back.. My team is up collecting.. $3.10 possible next.. The dip was a blessing🥦🥦🥦🥦

User Image Hogfarmer Posted - 06/30/22

$ATHA That wall at 3.00 must be made from steel

User Image 117Cavanaugh Posted - 06/30/22

$ATHA Go green already. Last week's reaction to the data was absurd.

Analyst Ratings
Berenberg Buy Apr 21, 22
Goldman Sachs Neutral Dec 15, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
MOEBIUS HANS Chief Medical Office.. Chief Medical Officer Jun 28 Buy 2.88 10,000 28,800 52,955 06/30/22
Worthington Mark General Counsel General Counsel Jun 22 Sell 2.69 2,614 7,032 19,097 06/24/22
MILESON GLENNA Chief Financial Offi.. Chief Financial Officer Jun 22 Sell 2.69 2,614 7,032 109,167 06/24/22
Litton Mark James Chief Executive Offi.. Chief Executive Officer Jun 22 Sell 2.69 7,960 21,412 128,555 06/24/22
Lenington Rachel Chief Operating Offi.. Chief Operating Officer Jun 22 Sell 2.69 4,193 11,279 5,807 06/24/22
CHURCH KEVIN Executive VP, Resear.. Executive VP, Research Jun 22 Sell 2.69 2,614 7,032 57,695 06/24/22
CHURCH KEVIN Executive VP, Resear.. Executive VP, Research Jun 08 Option 1.35 2,500 3,375 50,309 06/10/22
MILESON GLENNA Chief Financial Offi.. Chief Financial Officer Apr 12 Option 10.64 3,000 31,920 100,060 04/12/22
CHURCH KEVIN Executive VP, Resear.. Executive VP, Research Feb 18 Option 1.19 3,152 3,751 47,566 02/18/22